

Fecha del CVA

31/05/2023

## Parte A. DATOS PERSONALES

Nombre *	IGNACIO		
Apellidos *	PÉREZ VALERO		
Sexo *		Fecha de Nacimiento *	
DNI/NIE/Pasaporte *		Teléfono *	
URL Web			
Dirección Email			
Identificador científico	Open Researcher and Contributor ID (ORCID) *		
	Researcher ID		
	Scopus Author ID		

\* Obligatorio

### A.1. Situación profesional actual

Puesto	Facultativo Especialista en Medicina Interna		
Fecha inicio	2021		
Organismo / Institución	Servicio Andaluz de Salud. Consejería de Salud de Córdoba		
Departamento / Centro	Corporació Sanitària Parc Taulí / Hospital Universitario Reina Sofía		
País		Teléfono	
Palabras clave			

### A.3. Formación académica

Grado/Master/Tesis	Universidad / País	Año
Programa Oficial de Doctorado en Medicina y Cirugía	Universidad Autónoma de Madrid / España	2016
Licenciado en Medicina y Cirugía	Universidad de Alcalá / España	2003

A.4. Indicadores generales de calidad de la producción científica Total citations: 514. H-index: 18.

## Parte B. RESUMEN LIBRE DEL CURRÍCULUM

- IMIBIC: Investigador colaborador del Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) del Grupo GC-26 - Virología Clínica y Zoonosis desde 2021 a la actualidad.
- CIBER: Investigador colaborador del CIBER ENFERMEDADES INFECCIOSAS.CB21/13/00083 desde el año 2021.

## Parte C. MÉRITOS MÁS RELEVANTES

## C.1. Publicaciones

AC: Autor de correspondencia; (nº x / nº y): posición firma solicitante / total autores. Si aplica, indique el número de citaciones

- 1 Artículo científico. Corona-Mata D; Rivero-Juárez A; Camacho Á; et al; Rivero A; Pérez-Valero I. (15/16). 2023. Efficacy of a comprehensive strategy for the detection and treatment of hepatitis C infection in a population attending addiction centres. *Frontiers in Public Health*. ISSN 2296-2565.  
<https://doi.org/10.3389/fpubh.2023.1092960>
- 2 Artículo científico. Pérez-Valero I; Corona D; Martínez N; López-Cavanillas M; Lluís C; Luque I. (1/6). 2023. Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review. *Expert review of anti-infective therapy*. 21-6, pp.655-665. ISSN 1478-7210.  
<https://doi.org/10.1080/14787210.2023.2203914>
- 3 Artículo científico. Palmier E; De Miguel R; Montejano R; et al; Martín-Carbonero L.; Pérez-Valero I. (10/15). 2023. Three-year efficacy of switching to dolutegravir plus lamivudine: A real-world study. *HIV medicine*. ISSN 1464-2662.  
<https://doi.org/10.1111/hiv.13500>
- 4 Artículo científico. LUZ Martín Carbonero; Rosa de Miguel; Lucia Serrano; et al; Juan González García. 2022. Acute hepatitis B among HIV positive persons: A two-decade review of cases from a Spanish cohort. *Enferm Infecc Microbiol Clin (Engl Ed)*. ELSEVIER. 40-3, pp.121-124. <https://doi.org/10.1016/j.eimce.2020.09.008>
- 5 Artículo científico. Busca C; Sánchez-Conde M; Rico M; et al; Montes ML.; Pérez-Valero I. (10/19). 2022. Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens. *OPEN FORUM INFECTIOUS DISEASES*. 9-7. ISSN 2328-8957.  
<https://doi.org/10.1093/ofid/ofac279>
- 6 Artículo científico. Cabello-Úbeda A; Baeza AG; García JT; et al; Pérez-Valero I.(18/18). 2022. Changes in Quality of Sleep, Mood, and Other Neuropsychiatric Symptoms After Switching Dolutegravir/Lamivudine/Abacavir to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Randomized Study of People With Human Immunodeficiency Virus With Poor Sleep Quality: GESIDA 10418. *OPEN FORUM INFECTIOUS DISEASES*. 9-9. ISSN 2328-8957. <https://doi.org/10.1093/ofid/ofac345>
- 7 Artículo científico. Chiara Fanciulli; Juan Berenguer; Carmen Busca; et al; GeSIDA 8514 Study Group. 2022. Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019. *HIV Medicine*. Wiley. <https://doi.org/10.1111/hiv.13229>
- 8 Artículo científico. Micán R; de Gea Grela A; Cadiñanos J; et al; Martín-Carbonero L.; Pérez Valero I. (11/15). 2022. Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients. *AIDS*. 36-14, pp.1941-1947. ISSN 0269-9370.  
<https://doi.org/10.1097/QAD.0000000000003311>

- 9 Artículo científico. Ignacio Pérez Valero (AC); Jordi Blanch; Esteban Martinez. (1/3). 2022. Perception of HIV physicians in Spain towards diagnosis and management of neuropsychiatric comorbidities in people with HIV. HIV

MEDICINE. WILEY. 00, pp.1-9.

<https://doi.org/10.1111/hiv.13296>

- 10 Artículo científico. Hortensia Álvarez; Marta Rava; Cristina Martínez; et al; CORIS Study Group. 2022. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort. HIV MEDICINE. WILEY.  
<https://doi.org/10.1111/hiv.13265>
- 11 Artículo científico. López-López P; Frias M; Camacho A; et al; Rivero A; Pérez-Valero I. (8/11). 2022. Seroreversion of IgG anti-HEV in HIV cirrhotic patients: A long-term multi-sampling longitudinal study. Transboundary and Emerging Diseases. ISSN 1865-1674.  
<https://doi.org/10.1111/tbed.14486>
- 12 Artículo científico. Mican R; Busca Arenzana C; Vasquez J; Daroca G; Perez-Valero I; Martin-Carbonero L. (5/6). 2021. Hepatitis B reactivation after tenofovir withdrawal in an HIV-infected patient with history of cured hepatitis B virus infection and poor immunological status. AIDS. 35-10, pp.1707-1708. ISSN 0269-9370.  
<https://doi.org/10.1097/QAD.0000000000002941>
- 13 Artículo científico. Perez-Valero, I; Llibre, JM; Castagna, A; et al; Haubrich, R. (1/12). 2021. Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 86-4, pp.490-495. ISSN

1525-4135. <https://doi.org/10.1097/QAI.0000000000002595>

- 14 Artículo científico. Martín-Carbonero L; de Miguel R; Serrano L; et al; Montes M.; Pérez-Valero I. (10/13). 2020. Acute hepatitis B among HIV positive persons: A two-decade review of cases from a Spanish cohort. Enfermedades infecciosas y microbiología clínica (English ed.). ISSN 2529-993X. <https://doi.org/10.1016/j.eimc.2020.09.012>
- 15 Artículo científico. Perez Valero I; Cabello A; Ryan P; et al; González García JJ.(1/14). 2020. Randomized Trial Evaluating the Neurotoxicity of Dolutegravir/Abacavir/Lamivudine and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: GESIDA 9016. OPEN FORUM INFECTIOUS DISEASES. 7-12. ISSN 2328-8957. <https://doi.org/10.1093/ofid/ofaa482>
- 16 Artículo científico. Pérez-Valero I; Ellis R; Heaton R; et al; Letendre S.(1/15). 2019. Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects. AIDS. 33-3, pp.475-781. ISSN

0269-9370. <https://doi.org/10.1097/QAD.0000000000002074>

- 17 Artículo científico. Alejos B; Suárez-García I; Bisbal O; et al; Jarrín I; CoRIS cohort.2019. Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors. PLOS ONE. 14-8. ISSN

1932-6203. <https://doi.org/10.1371/journal.pone.0221598>

- 18 Artículo científico. Resino S; Navarrete-Muñoz MA; Blanco J; et al; CoRIS and the HIV Biobank integrated in the Spanish AIDS Research Network Project RIS/EPIC. 2019. IL7RA rs6897932 Polymorphism is Associated with Better CD4 + T-Cell Recovery in HIV Infected Patients Starting Combination Antiretroviral Therapy. BIOMOLECULES. 9-6, pp.233. ISSN 2218-273X. <https://doi.org/10.3390/biom9060233>
- 19 Artículo científico. Suárez-García I; González J; Berenguer J; García F; Portilla J; Muga R; Moreno S; Jarrín I; Cohort of the Spanish HIV Research Network (CoRIS).2019. Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010-2015. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 37-9, pp.580-587. ISSN 0213-005X. <https://doi.org/10.1016/j.eimc.2019.02.007>
- 20 Artículo científico. Berenguer J; Gil-Martin Á; Jarrin I; et al; González-García JJ; Madrid-CoRe Study Group.2019. Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfecting individuals. AIDS. 33-4, pp.685-689. <https://doi.org/10.1097/QAD.0000000000002103>
- 21 Artículo científico. Eron JJ; Orkin C; Cunningham D; et al; Opsomer M; EMERALD study group.2019. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1. ANTIVIRAL RESEARCH. 170. ISSN 0166-3542. <https://doi.org/10.1016/j.antiviral.2019.104543>
- 22 Artículo científico. Letendre S; Bharti A; Perez-Valero I; et al; CNS HIV AntiRetroviral Therapy Effects Research (CHARTER) Group.(3/12). 2018. Higher Anti-Cytomegalovirus Immunoglobulin G Concentrations Are Associated With Worse Neurocognitive Performance During Suppressive Antiretroviral Therapy. CLINICAL INFECTIOUS DISEASES. 67-5, pp.770-777. ISSN 1058-4838. <https://doi.org/10.1093/cid/ciy170>
- 23 Artículo científico. Montejano R; Stella-Ascariz N; Monge S; et al; Arribas JR.; Pérez-Valero I. (5/18). 2018. Impact of Nucleos(t)ide Reverse Transcriptase Inhibitors on Blood Telomere Length Changes in a Prospective Cohort of Aviremic HIV-Infected Adults. JOURNAL OF INFECTIOUS DISEASES. 218-10, pp.1531-1540. ISSN 0022-1899. <https://doi.org/10.1093/infdis/jiy364>
- 24 Artículo científico. Montejano, R.; De Miguel, R.; Bernardino, J.; et al; Arribas, J.2018. Integrase inhibitors and virological failure: a cohort analysis. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 21. ISSN 1758-2652.
- 25 Artículo científico. Pérez-Valero I; Pasquau J; Rubio R; et al; GESIDA 7011 Study Group members.(1/14). 2018. Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 73-9, pp.2444-2451. ISSN

0305-7453. <https://doi.org/10.1093/jac/dky212>

- 26 Artículo científico. González-Baeza A; Dolengevich-Segal H; Pérez-Valero I; et al; Ryan P. (3/16). 2018. Sexualized Drug Use (Chemsex) Is Associated with High-Risk Sexual Behaviors and Sexually Transmitted Infections in HIV-Positive Men Who Have Sex with Men:

- Data from the U-SEX GESIDA 9416 Study. AIDS PATIENT CARE AND STDS. 32-3, pp.112-118. ISSN 1087-2914. <https://doi.org/10.1089/apc.2017.0263>
- 27 Kostaki, Evangelia-Georgia; Flampouris, Andreas; Karamitros, Timokratis; et al; CoRIS. 2019. Spatiotemporal Characteristics of the Largest HIV-1 CRF02\_AG Outbreak in Spain: Evidence for Onward Transmissions. FRONTIERS IN MICROBIOLOGY. 10. ISSN 1664-302X. <https://doi.org/10.3389/fmicb.2019.00370>
  - 28 Jimenez-Sousa, Maria A.; Luis Jimenez, Jose; Fernandez-Rodriguez, Amanda; et al; LTNP Cohort. 2019. VDR rs2228570 Polymorphism Is Related to Non-Progression to AIDS in Antiretroviral Therapy Naive HIV-Infected Patients. JOURNAL OF CLINICAL MEDICINE. 8. ISSN 2077-0383. <https://doi.org/10.3390/jcm8030311>
  - 29 Montejano, R.; Alejos, B.; De Miguel, R.; et al; Bernardino, J.2018. Effect of tenofovir alafenamide (TAF) initiation on lipid profile in La Paz Hospital cohort: consequence of TDF withdrawal or TAF initiation?. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 21. ISSN 1758-2652.
  - 30 Gonzalez-Baeza, A.; Rua-Cebrian, G.; Montejano, R.; Bernardino, J.; Gonzalez, J.; Perez-Valero, I.2018. Prevalence of cognitive impairment in a cohort of HIV-infected patients older than 60 years. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 21. ISSN 1758-2652.

### C.3. Proyectos y Contratos

- 1 Proyecto. PIE15/00065, The risk of infections in several pathologies: a thorough study with clinical tools development for personalised medicine. Eduardo Manuel López Collazo. (Instituto de Investigación Hospital Universitario La Paz). 01/01/201630/06/2020. Miembro de equipo.
- 2 Proyecto. A phase IV, open-label, randomised, pilot clinical trial designed to evaluate the potential neurotoxicity of dolutegravir/lamivudine/abacavir in neurosymptomatic HIV patients and its reversibility after switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. DREAM Study. Fundación SEIMC-GESIDA. Ignacio Perez Valero. (Hospital Universitario La Paz). 12/12/2016-30/12/2019. 386.007 €.
- 3 Proyecto. Clinic for managing neurocognitive disabilities in people aging with HIV. Gilead Sciences, S.L.. Ignacio Pérez Valero. (Instituto de Investigación Hospital Universitario La Paz). 01/09/2016-01/09/2017.46.000 €.